This review discusses the management of resistant cytomegalovirus and prevention
strategies for fatal therapy failures. Five drugs, ganciclovir/valganciclovir, cidofovir, foscarnet …

This editorial summarizes recent developments in the management of ganciclovir-resistant
human cytomegalovirus (HCMV) infections. All current drugs available for systemic …

The study of human cytomegalovirus (HCMV) antiviral drug resistance has enhanced
knowledge of the virological targets and the mechanisms of antiviral activity. The currently …

Human cytomegalovirus (HCMV) can cause severe disease in patients with compromised or
immature immune systems. Currently approved pharmacotherapies for the treatment of …

Resistance of cytomegalovirus (CMV) to antiviral agents is a well-recognized phenomenon
that has been observed in the laboratory and in the clinical setting. Infections caused by …

There are at present five compounds that have been officially licensed for the treatment of
human cytomegalovirus (HCMV) infections: ganciclovir [GCV, 9-(1, 3-dihydroxy-2 …

Human cytomegalovirus (HCMV) is ubiquitous worldwide and elicits global health problems.
The diseases associated with HCMV are a serious threat to humans, especially for the sick …

Cytomegalovirus (CMV) is an opportunistic pathogen associated with significant morbidity
and mortality in immunocompromised hosts. Antiviral agents specifically targeting CMV were …

Ganciclovir (GCV), the therapy of choice for human cytomegalovirus (CMV) infections and
foscarnet, a drug used to treat GCV-resistant CMV infections was approved more than …

Antiviral-resistant cytomegalovirus infection remains a feared complication of transplantation
but is less frequently seen in AIDS patients in the current era. New research on resistance …